1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsReGRoW – Clinical Trial Funding for LMICs is sponsored by Cures Within Reach. Provides grants to scientists and clinicians in LMICs for repurposing existing therapies to treat diseases prevalent in their communities.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries - REMEDi4ALL Hit enter to search or ESC to close Funding Calls Database « All Calls ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries This Request for Proposals (RFP) provides grants for clinical repurposing trials led by researchers and clinicians based in low and lower-middle income countries (LMICs), as defined by the World Bank (https://data.
worldbank. org/products/wdi-maps). This RFP is seeking clinical repurposing trials to address any unsolved disease facing patients in LMICs.
However, CWR has a preference for trials that address high disease burden (https://ourworldindata. org/burden-of-disease) whether non-communicable diseases; communicable diseases; maternal, neonatal and nutritional diseases; or injuries.
Repurposed therapies must be approved and/or generally recognized as safe for human use by some regulatory agency, such as the US Food and Drug Administration, European Medicines Agency, Health Canada or Japan’s Pharmaceuticals and Medical Devices Agency, and can include generic drugs, nutraceuticals or indigenous therapies.
These repurposed therapies must be tested in a new indication for which they are not already approved or used widely in clinical practice as standard of care. Repurposed therapies also may be added to current standard of care to improve patient outcomes and/or quality of life. CWR is accepting budgets of up to US$65,000 for this funding opportunity.
All submissions must include ideas and/or plans to engage the community of interest before, during and after the proposed clinical trial. CWR will provide up to US$7,500 in additional financial support for community engagement, with at least US$4,000 required for community engagement. CWR has a 2-stage submission process, starting with the brief Letter of Intent (LOI).
The top-rated LOI submissions will be invited to submit a full scientific proposal. All submissions are ProposalCentral (https://proposalcentral. com).
Search for “Cures Within Reach” and submit your proposal using the Repurposing Research in LMICs program. The LOI submission deadline is 11:59pm U.S. Eastern Time on March 28, 2025. Deadline First stage (LOI / pre-proposal) Announcement of Applicants selected for stage 2 Deadline Full Application Grant Decision – Final Decision – Awarding Unfortunatly this funding call is not open for applications.
Non-dilutive (grant, donation etc) Philanthropic organisation – national The REMEDi4ALL project has received funding from the European Union’s Horizon Europe Research & Innovation programme under grant agreement No 101057442.
About Us REMEDi4ALL is an EU-funded research initiative transforming drug repurposing by building a state-of-the-art platform, uniting global expertise, and accelerating access to cost-effective treatments for patients in need. DEMO PROJECTS To test the platform’s viability and robustness we support real-world projects on infectious diseases, rare cancers, and rare/ultra rare diseases.
i DR The International Drug Repurposing (iDR) Conference Series is an annual global conference series where key opinion leaders from research and patient communities, funders, regulators and representatives from the private sector participate to collectively advance innovative drug repurposing in Europe and beyond.
Explore the iDR conference series 2026 International Drug Repurposing Conference Medicines Reimagined Newsletter DRUG REPURPOSING CONCIERGE Get expert guidance for your drug repurposing project. Through a 30-minute consultation, our experts help you explore scientific support, regulatory pathways, advocacy opportunities and funding options.
With 250+ inquiries answered and a 100% response rate, the Concierge is your first stop within REMEDi4ALL for navigating the path from discovery to market. PROJECT PARTNERING PORTAL Advance your repurposing project with REMEDi4ALL through a formalised partnership.
Following a thorough evaluation process, selected projects are onboarded to work hand-in-hand with multidisciplinary teams, providing support from early discovery to regulatory approval to patient access. All potential applicants are strongly advised to engage with the Drug Repurposing Concierge before submitting partnering proposals.
REMED i 4ALL Repurposing Academy A range of training resources designed to provide a comprehensive understanding of the drug repurposing landscape. REMEDi4ALL Digital Academy The Digital Academy is our online home for on demand training on repurposing. REMEDi4ALL Bootcamps Our Bootcamps are short, in person training events that provide the chance to meet others in the drug repurposing field.
REMEDi4ALL Webinars Our webinars provide accessible, live training on specific stages of the repurposing journey. REMEDi4ALL Hackathon Join a small team of international trainees to learn on a week-long residential course where you aim to plan the development of a repurposing candidate. Resources We’re a dynamic community dedicated to drug repurposing, we produce a wide range of valuable resources.
Explore our collection here. In-silico Drug Repurposing Catalogue Practical Guide to Creating Joint Funding Calls for Drug Repurposing Research Framework for Judging the Project Value of Repurposed Medicines MEDICINES REIMAGINED Join a vibrant community to connect and collaborate to advance drug repurposing. FUNDERS NETWORK Public and private funders worldwide driving innovation in drug repurposing.
According to the current listing, eligibility includes: Scientists and clinicians in LMICs conducting clinical research. Confirm the full requirements in the official notice before applying.
The current listing shows up to $70,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
ReGRoW – Clinical Trial Funding for LMICs is funded by Cures Within Reach. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Clinical Repurposing for Veterans Initiative is sponsored by Cures Within Reach. This initiative focuses on finding and funding clinical repurposing trials that address unmet and high-priority medical needs of veterans and active military, including brain injuries. This is a very strong fit for a nonprofit focused on neurological conditions and veterans.
Funding Opportunities / RFPs (Cures Within Reach) is sponsored by Cures Within Reach. Cures Within Reach's mission is to improve patient quality and length of life by leveraging the speed, safety and cost-effectiveness of testing already approved therapies for new indications that serve philanthropic and/or commercial uses, driving more treatments to more patient…
AI Validation - Clinical Trials to Validate AI-Driven Drug Repurposing is sponsored by Cures Within Reach. This program supports investigator-initiated, proof-of-concept, Phase I or Phase IIA clinical trials to validate AI-driven repurposing opportunities for approved therapies in any unsolved disease. Eligible trials must include AI-generated data as part of the preclinical support.
On July 30, 2026, five food and farming nonprofits sued USDA in the Western District of Washington over grant terms and conditions that restrict what grantees may say and do — including with money that never came from the federal government. Twenty states and DC filed a parallel challenge in March. Here is what the conditions actually say and what recipients should do before their next award letter arrives.
Read articleHRSA-26-078 splits $9.1 million among roughly 10 Public Health Training Centers, with awards up to $910,000 and applications due July 17, 2026. Eligibility runs to accredited schools of public health and other nonprofit training institutions. Here's why the winning applications are the ones that can prove an existing, mapped relationship with state and local health departments — not the ones promising the slickest coursework.
Read articleThe Department of Education's May 19 final rule activates Workforce Pell on July 1, 2026, opening federal aid to short-term training programs as brief as 8 weeks. Governors and state workforce boards — not accreditors — pick the eligible industries, and only programs that pass earnings-vs-cost gates make the list.
Read article